

ASX Announcement

Medical University of Vienna publishes new mimotope cancer vaccine results

- New Strategy Toward B Cell-Based Immunotherapy by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors
- Ground-breaking research from Vienna, conducted under the leadership of Imugene SAB member Professor Dr Ursula Wiedermann

SYDNEY, Australia, 28 May 2020: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced that its preclinical research related to its mimotope vaccines targeting immune checkpoint inhibitors has been accepted and published in the prestigious journal *Frontiers in Immunology* [1].

The ground-breaking research from Vienna, conducted under the leadership of Imugene SAB member Professor Dr Ursula Wiedermann with Dr Joshua Tobias as lead author, has identified mimotope peptides that when incorporated into Imugene’s proprietary immunotherapeutic vaccine delivery platform, generate antibodies that bind specifically to immune cells expressing the PD1 biomarker. The naturally produced antibodies block a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells, as shown in animal models of breast cancer.

Imugene MD & CEO Leslie Chong said “Development of this new immunotherapy expands our pipeline and further transforms Imugene into a multi-asset biopharmaceutical company.”

The concept of teaching and inducing the body to generate its own antibodies targeting PD1 expressing cells represents a paradigm shift in oncology, and is the first journal report of treating cancer by this method. The publication is a detailed study of the mechanism of action of active immunisation targeting immune checkpoint regulator PD1. The results validate and support the B cell “epitope” contained in Imugene’s PD1-Vaxx, scheduled to commence a Phase 1 trial in 2020.

Imugene’s PD1-Vaxx is a B-cell cancer immunotherapy designed to treat tumors such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect similar to Keytruda®, Opdivo® and the other immune checkpoint inhibitor monoclonal antibodies that are

transforming treatment of a range of cancers. The primary objective of the phase 1 trial is to determine safety and an optimal biological dose as monotherapy and in combination with immune checkpoint inhibitors. Efficacy, tolerability and immune response will also be measured.

[1] Front. Immunol., 27 May 2020 | <https://doi.org/10.3389/fimmu.2020.00895>

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

T: +61 458 040 433

Follow us on Twitter [@TeamImugene](#)

Like us on Facebook [@Imugene](#)

Connect with us on LinkedIn [@Imugene Limited](#)

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer